Indications
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). Refixia can be used for all age groups.
Composition
- Active substance
- nonacog beta pegol
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Refixia
- Active substance
- nonacog beta pegol
- ATC code
- B02BD04
- Therapeutic area
- Hemophilia B
- Marketing authorisation holder
- Novo Nordisk A/S
- Status
- Authorised
- EU authorisation
- 2 Jun 2017